KT-253

· Kymera Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for KT-253, covering 2025-01-27 to 2025-01-27. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors [Phase 1]

See pricing